NCT02359877View on ClinicalTrials.gov

Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

December 31, 2015

Conditions
Healthy
Interventions
DRUG

BCD-054

DRUG

Rebif

DRUG

Avonex

Trial Locations (1)

197342

"OOO BioEk", Saint Petersburg

Sponsors

Lead Sponsor

Biocad
All Listed Sponsors
lead

Biocad

INDUSTRY

NCT02359877 - Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers | Biotech Hunter | Biotech Hunter